Vitamin D receptor levels in colorectal cancer. Possible role of BsmI polymorphism
Issue date
2008Author
Parisi Capdevila, Eva
Cardús i Figueras, Anna
Valcheva, Petya
Suggested citation
Parisi Capdevila, Eva;
Reñé Espinet, Josep Maria;
Cardús i Figueras, Anna;
Valcheva, Petya;
Piñol Felis, Carme;
Valdivielso Revilla, José Manuel;
Fernández i Giráldez, Elvira;
.
(2008)
.
Vitamin D receptor levels in colorectal cancer. Possible role of BsmI polymorphism.
Journal of Steroid Biochemistry & Molecular Biology, 2008, vol. 111, núm. 1-2, p. 87-90.
https://doi.org/10.1016/j.jsbmb.2008.05.001.
Metadata
Show full item recordAbstract
A high expression of vitamin D receptor (VDR) in colorectal cancer (CRC) tumoral tissue has been related
to a good prognosis and it has been proposed that it could be a good biological marker of CRC progression.
Nevertheless, there are no previous studies that compare the VDR expression in tumoral towards normal
tissue of the same CRC patient in relation to VDR BsmI genotype.
We collected normal and tumoral tissue samples, as well as blood samples, from CRC patients (n = 170)
and controls (n = 122). VDR genotyping was performed and BsmI homozygous patients were selected
(CRC = 50, Cont = 32). VDR mRNA and protein levels were analyzed. We also measured 25-Hydroxyvitamin
D serum levels.
We found no differences in the polymorphism distribution in tumoral versus normal tissue (control:
BB = 15.7%, bb = 41.3%, Bb = 43%; CRC: BB = 14.2%, bb = 41.9%, Bb = 43.9%). Furthermore, VDR levels decreased
in colonic cancer tissue (mean: 3.03) versus normal mucosa (11.62) from the same patient (p < 0.001),
but this decrease was similar in both genotypes. There were differences in 25-Hydroxyvitamin D3 levels
between the CRC and the control group (CRC = 8.65 ng/ml, Cont = 18.15 ng/ml).
In conclusion, we found a decrease in VDR levels in tumoral compared with normal mucosa from the
same patient. This difference is independent of the BsmI polymorphism.